health · humanitarian · family: designed for the wrong person
antivenom waits at hospitals victims can't reach
Snakebite kills up to 138,000 people a year because antivenom treatment was designed for hospitals that victims can't reach
Problem statement
Snakebite envenoming kills 81,000 to 138,000 people annually and permanently disables an estimated 400,000 more, overwhelmingly in rural agricultural communities across South Asia and sub-Saharan Africa. The only definitive treatment — antivenom — is in many countries held only at facilities staffed by doctors, with the resources to manage adverse reactions such as anaphylaxis. But the victims are subsistence farmers and agricultural laborers bitten in fields long distances from the nearest hospital. The treatment system was designed around hospital capacity when the actual bottleneck is what happens in the community in the critical hours between the bite and reaching a facility. WHO published the first of its public-benefit Target Product Profiles for antivenoms in June 2023, but the TPPs alone cannot solve the access problem because the barrier is not antivenom quality — it's the entire system that sits between a snakebite and a hospital bed.
Why this matters
WHO designated snakebite envenoming as a Category A neglected tropical disease in 2017. The burden falls almost entirely on the world's poorest people: subsistence farmers, agricultural workers, and children in rural communities in sub-Saharan Africa and South Asia. The economic impact extends far beyond mortality — survivors often suffer permanent disability (amputation, loss of limb use, tissue damage) that can leave victims mired in poverty. The antivenom market is at risk of collapse in parts of Africa, with availability already declined or gone in some areas: out-of-pocket payment is often the main financing mechanism, meaning victims must choose between paying for treatment they may not be able to afford and risking death. Several manufacturers have exited the market due to low demand, creating a vicious cycle: fewer products → higher prices → lower demand → fewer manufacturers. WHO's 2030 target is to halve snakebite mortality and disability.
What’s been tried and why it hasn’t worked
Hospital-based antivenom programs have been the standard approach for decades, but they fail for structural reasons: (1) most victims are bitten in rural areas, often long distances from the nearest facility with antivenom and trained staff; (2) out-of-pocket financing means patients delay seeking care or accept under-dosing to reduce cost; (3) in many communities across South Asia and sub-Saharan Africa, snakebite is associated with supernatural causes — deity punishment, witchcraft, or spiritual affliction — and traditional healers are often the first source of care, with hospital care sought only after consulting them; (4) community members perform harmful first-aid practices (tourniquets, plant- and animal-based remedies) that delay effective treatment. Supply of antivenom at peripheral health facilities is often unreliable, and in many countries policy keeps antivenom at secondary or tertiary referral centres rather than primary health centres; antivenoms that are not freeze-dried also depend on a cold chain that is often absent in remote settings. Knowledge of snakebite management among health workers is often poor, and health workers in remote settings may be apprehensive about treating snakebite for fear of being unable to manage antivenom reactions. Community education campaigns targeting prevention and care-seeking behavior face deeply rooted community resistance — programme staff report that community members come to listen but do not always adopt the recommendations, and that language barriers can leave an organization seen as an "outsider."
What would unlock progress
A fundamentally different product architecture: community-level treatments that don't require a doctor-staffed facility, cold chain storage, or trained clinicians. Emerging next-generation treatments include small-molecule therapies (e.g., varespladib, a phospholipase A2 inhibitor that WHO's strategy names as a promising prehospital adjunctive treatment) and engineered antibody cocktails, which are expected to differ from conventional antivenoms in administration routes. These approaches could ease the hospital bottleneck. In parallel, the behavioral challenge requires community-designed interventions — not top-down education campaigns but programs co-created with traditional healers and community leaders that integrate biomedical treatment into existing community health-seeking frameworks rather than competing with them. Telemedicine-guided treatment, where a remote expert assists a local health worker through an antivenom infusion via video, could bridge the expertise gap without requiring specialists in every rural facility.
Entry points for student teams
A student team could design a community-level snakebite first-response kit and protocol for community health workers in one named district — evidence-based first aid, a visual or app-based species-identification aid, referral pathway mapping (nearest facilities stocking antivenom, transport options, estimated travel times), and a telemedicine connection for remote physician guidance — and build the identification and referral layers entirely on public data: WHO's Snakebite Information and Data Platform publishes range maps for the medically important venomous snakes plus a searchable antivenom product database with no login, and GBIF's open occurrence API returns georeferenced records for the relevant species that can be clipped to a district boundary. Evaluating it without field access is the part to design honestly: toxinologists, emergency clinicians from the target region's diaspora, and staff of NGOs working on snakebite can be recruited by video to review species-ID accuracy, first-aid content and referral logic, while the field test with community health workers — an in-country partner, local ethics approval, and months of relationship-building that belong to that partner — becomes the protocol and training curriculum the team writes and hands over. A team with behavioral science skills could treat the traditional-healer question the same way, synthesizing the published community-engagement and barrier literature into a co-design facilitation guide and pre-registered evaluation plan for positioning biomedical first response as complementary to existing healing practice, ready for an NGO or ministry to run, rather than attempting the community partnership itself inside a semester.
Genes
Structural cousins: stuck the same way, in other fields
Sources
WHO, "Improving treatment for snakebite patients," (accessed 2026-02-14). WHO, "Snakebite envenoming fact sheet," WHO, "First WHO guidance on snakebite treatments published," 23 June 2023, Supplemented with: "Barriers and enablers of community engagement practices for the prevention of snakebite envenoming in South Asia," PMC, 2022, "Community-based interventions for bite prevention, improved care-seeking and appropriate first aid in snakebite," PMC, 2022, "Access to antivenoms in the developing world: A multidisciplinary analysis," PubMed, 2021, "Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming," PLOS NTDs, 2019, go to source 1 ↗ go to source 2 ↗ go to source 3 ↗ go to source 4 ↗ go to source 5 ↗ go to source 6 ↗ go to source 7 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
- This brief is the strongest example of `failure:wrong-stakeholder` in the collection: the entire treatment system was designed for hospitals (the provider as the key actor) when the actual critical actor is the community — victims, families, traditional healers, community health workers — who must make correct decisions in the first hours after a bite. The hospital is too far away to be the relevant stakeholder.
- The cultural beliefs barrier (snakebite as supernatural punishment) is distinct from the `failure:adoption-barrier` pattern in the assistive technology brief — it's not that people won't use a solution that's available, but that they operate within a fundamentally different causal framework about the nature of the problem.
- The manufacturer exit → price increase → demand decline → more manufacturer exit spiral is a market failure that mirrors the LFP battery recycling economics problem in `energy-lfp-battery-recycling-economics` — in both cases, the economics create a death spiral rather than a stable market.
- Cross-domain connection: the "last mile" treatment access problem is structurally identical to the cold chain first-mile problem in `agriculture-smallholder-cold-chain-access` — distributed, rural, infrastructure-poor settings where centralized solutions fail.
- Wellcome Trust launched a Global Snakebite Taskforce at the 78th World Health Assembly in 2025, signaling renewed institutional attention (not in any source named on this page; unchecked in the 2026-09-30 pass). Student teams working on this problem would be entering a field with growing resources and policy attention.
Reconciliation 2026-08-21: the C37 realism triage (score 2) flagged both entry points — a training curriculum "tested with community health workers" and a partnership intervention with traditional healers — as requiring endemic-region field access, local ethics approval and relationship-building beyond a semester; the flag holds for the evaluation halves of both, though the design halves (kit, decision-support tool, referral map, facilitation guide) were always sound and are kept. The repair names public data the identification and referral layers can actually be built on, moves evaluation to reviewers reachable by video (toxinologists, diaspora clinicians, snakebite NGOs), and makes the CHW field test and the healer co-design the protocols handed to the in-country partner who owns that access. Resources verified by fetch on 2026-08-21: WHO's Snakebite Information and Data Platform (https://www.who.int/teams/control-of-neglected-tropical-diseases/snakebite-envenoming/snakebite-information-and-data-platform, interface at https://snbdatainfo.who.int/, HTTP 200), publicly accessible without login and carrying range maps of medically important venomous snakes, an antivenom products database and country burden data; and the GBIF occurrence API (https://api.gbif.org/v1/occurrence/search), open with no key, returning 9,524 records for Bitis arietans and 2,348 for Naja nigricollis on the date of check. Body sections and Genome Tags are unchanged.
Reconciliation 2026-09-30: Whole-write-up check against every source named on this page, all fetched 2026-09-30. Read in full: the WHO "Preventing and controlling snakebite envenoming" activities page; the WHO snakebite envenoming fact sheet (dated 17 September 2026); the WHO news item "First WHO guidance on snakebite treatments published" (23 June 2023, https://www.who.int/news/item/23-06-2023-first-who-guidance-on-snakebite-treatments-published, found from a link on the activities page); Ten Have, Ooms, Waldmann and Reed 2022 (Toxicon: X, https://pmc.ncbi.nlm.nih.gov/articles/PMC9764250/); the Bhaumik et al. Cochrane protocol 2022 (https://pmc.ncbi.nlm.nih.gov/articles/PMC9491156/); Potet et al. 2021 (Toxicon: X; the PubMed page returned a browser challenge, so the abstract was taken from the NCBI E-utilities record and the full text from https://pmc.ncbi.nlm.nih.gov/articles/PMC8578041/); Williams et al. 2019 (PLOS NTDs, https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007059); and the WHO Snakebite Information and Data Platform page, with https://snbdatainfo.who.int/ answering HTTP 200 and the GBIF occurrence API returning 9,749 Bitis arietans records on the day. Changes: (1) Title: "Snakebite Kills 138,000 People a Year" gave the top of a range as a flat count; WHO gives "up to 138 000" (fact sheet: 81 410 to 137 880), so the title now reads "Snakebite Kills Up to 138,000 People a Year Because Antivenom Treatment Was Designed for Hospitals That Victims Can't Reach". Display title unchanged. (2) The Source line entry for the June 2023 guidance now carries the date and address of the page that was read; nothing else on the Source line changed. (3) "Requires intravenous administration by trained clinicians in a hospital setting with capacity to manage anaphylactic reactions": no source says intravenous or hospital; Potet et al. say access is in many countries restricted to facilities staffed by doctors with resources to manage adverse reactions, and Ten Have et al. name fear of anaphylactic shock; the sentence now follows them. (4) "Hours from the nearest hospital" and "2–6 hours from the nearest facility": no source gives hours; Potet et al. say many victims must travel long distances; both now say long distances. (5) "WHO is now developing the first public-interest Target Product Profiles": WHO published the first of its public-benefit TPPs in June 2023; the sentence now says that. (6) "Plantation workers" is in no source; the fact sheet names agricultural workers; changed. (7) "Chronic pain, tissue necrosis" and "destroys agricultural livelihoods, plunging families into deeper poverty": the sources name amputation, loss of limb use and tissue damage, and say victims become mired in poverty; the sentence now says that. (8) "The antivenom market has collapsed in parts of Africa": the PLOS strategy says "a fragile market at risk of collapse", and the fact sheet says availability has declined significantly or disappeared in some areas and supply failure is imminent in Africa; softened to match. "Primary financing mechanism" became "often the main financing mechanism", Potet et al.'s wording. (9) "Traditional healers are the first and often only care-seekers": Ten Have et al. report patients sought hospital care only after consulting a traditional healer; "often only" is in no source; rewritten. "Spiritual affliction" is kept: Ten Have et al. name "deep-rooted religious and spiritual beliefs" among community members. (10) "Incision, suction, application of herbs": tourniquets are named by Ten Have et al. and plant-, animal- and mineral-based remedies by Potet et al.; incision and suction are in no source; the list now holds what the sources name. (11) The three sentences on stockpiling at peripheral centres failing from shelf life, cold chain and low bite frequency, on training programmes losing competence because bites are infrequent, and on villagers calling programmes "outsider" interventions that don't respect local knowledge, are not in any source. They were replaced with what the sources do say: unreliable peripheral supply and policies that keep antivenom at referral centres, cold chain often absent in remote settings, which Potet et al. say lyophilised antivenoms avoid, so the sentence names antivenoms that are not freeze-dried (Potet et al.); poor health-worker knowledge and apprehension about managing antivenom reactions (Potet et al.); community members listening but not adopting recommendations, and language barriers leaving an organization seen as an outsider (Ten Have et al.). (12) "IV administration", "repurposed", "broad-spectrum", "administered orally or intramuscularly by community health workers or even by the victim themselves", and "would bypass the hospital bottleneck entirely" are not in the sources; the PLOS strategy names varespladib, a phospholipase A2 inhibitor, as a promising prehospital adjunctive treatment, and Potet et al. say novel treatments will differ in administration routes; the passage now says that, and "would bypass entirely" became "could ease". (13) Telemedicine-guided treatment "being piloted in India" is in no source; the pilot claim was removed and the idea kept as a proposal. (14) The working note on a Wellcome Global Snakebite Taskforce at the 78th World Health Assembly rests on no source named here and is marked as unchecked. Confirmed and left as written: 81,000 to 138,000 deaths and 400,000 permanently disabled each year; antivenom as the only treatment; the highest-priority ("Category A") NTD listing in 2017; several manufacturers ceasing production for low demand and prices rising; the 2030 goal of halving deaths and disability; deity punishment and witchcraft as community explanations; that most victims are bitten in rural areas; under-dosing driven by cost; and the entry-point resources. Not checked: nothing else remained beyond the Wellcome note. A second reader went over every repair on the same day against the same sources, all fetched again on 2026-09-30, and made the three adjustments recorded above (spiritual affliction kept; freeze-dried qualifier; adjunctive). Genome Tags untouched.